Tymlos
Payments companies reported to CMS as associated with Tymlos. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tymlos, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tymlos
These are the largest totals companies reported as associated with Tymlos. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Felicia Cosman | West Haverstraw, NY | $101,081.27 | |
| Jacqueline Kernaghan | Springfield, PA | Medical | $64,087.41 |
| Kristi Tough Desapri | Winnetka, IL | Internal Medicine | $54,700.58 |
| Jonathan Greer | Boynton Beach, FL | Rheumatology | $50,692.48 |
| Edward Lewiecki | Albuquerque, NM | Internal Medicine | $50,441.52 |
| Steven Harris | Greenbrae, CA | Endocrinology, Diabetes & Metabolism | $44,820.83 |
| Pascal Dauphin | Hendersonville, TN | Endocrinology, Diabetes & Metabolism | $39,796.97 |
| John Bilezikian | New York, NY | Endocrinology, Diabetes & Metabolism | $30,897.90 |
| Andrea Singer | Washington, DC | Internal Medicine | $25,549.39 |
| Lynn Kohlmeier | Spokane, WA | Endocrinology, Diabetes & Metabolism | $21,381.51 |
Prescribed Tymlos?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.